Activity Overview
This educational activity is an archive of the live presentation held on May 29, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This
educational activity is directed toward medical oncologists, NPs/PAs, nurses,
pharmacists, and other HCPs involved in the treatment and management of
myelofibrosis.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent clinical trial data for new and emerging strategies to treat patients with MF
- Integrate appropriate evidence-based treatment strategies for patients with newly diagnosed and previously treated MF
- Examine best practices and clinical considerations for supportive care in MF
- Describe strategies to identify and manage toxicities associated with treatments for MF
Ruben A. Mesa, MD, FACP
President, Advocate Health Cancer National Service Line
President, Atrium Health Levine Cancer
Executive Director, Atrium Health Wake Forest Baptist
Comprehensive Cancer Center
Senior Vice President, Advocate Health
Vice Dean for Cancer Programs, Wake Forest University School of
Medicine
The Charles L. Spurr MD Professor of Medicine, Wake Forest
University School of Medicine
Winston-Salem, NC
Disclosures: Advisor, Consultant, Fee for Service Recipient: Blueprint, BMS, Disc, Genentech, GSK, Incyte, Novartis, PharmaEssentia, Sobi, Takeda; Grant/Research Funding: Incyte, PharmaEssentia
Andrew Kuykendall, MD
Assistant Member
Moffitt Cancer Center
Tampa, FL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Agis, Blueprint, Calytrix, Cellgate, Cogent, Deciphera, Geron, Incyte, Karyopharm, Merck, Opna, PharmaEssentia, Protagonist, Silence, Sobi, Takeda; Grant/Research Funding: Ajax, BMS, Blueprint, Geron, Incyte, Janssen, Kartos, MorphoSys, Novartis, Protagonist
Sangeetha Venugopal, MD, MS
Assistant Professor of Medicine
Leukemia Program, Division of Hematology
Sylvester Comprehensive Cancer Center
University of Miami Leonard M. Miller School of Medicine
Miami, FL
Disclosures: Advisory Board: Sobi; Grant/Research Funding (paid to institution): Oryzon Pharmaceuticals
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.